JP2016534148A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534148A5
JP2016534148A5 JP2016543991A JP2016543991A JP2016534148A5 JP 2016534148 A5 JP2016534148 A5 JP 2016534148A5 JP 2016543991 A JP2016543991 A JP 2016543991A JP 2016543991 A JP2016543991 A JP 2016543991A JP 2016534148 A5 JP2016534148 A5 JP 2016534148A5
Authority
JP
Japan
Prior art keywords
substituted
composition
use according
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534148A (ja
JP6564380B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/056369 external-priority patent/WO2015042297A1/en
Publication of JP2016534148A publication Critical patent/JP2016534148A/ja
Publication of JP2016534148A5 publication Critical patent/JP2016534148A5/ja
Application granted granted Critical
Publication of JP6564380B2 publication Critical patent/JP6564380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543991A 2013-09-20 2014-09-18 前立腺癌を治療するための化合物 Active JP6564380B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361880747P 2013-09-20 2013-09-20
US61/880,747 2013-09-20
PCT/US2014/056369 WO2015042297A1 (en) 2013-09-20 2014-09-18 Compounds for treating prostate can cancer

Publications (3)

Publication Number Publication Date
JP2016534148A JP2016534148A (ja) 2016-11-04
JP2016534148A5 true JP2016534148A5 (enExample) 2017-11-02
JP6564380B2 JP6564380B2 (ja) 2019-08-21

Family

ID=52689402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543991A Active JP6564380B2 (ja) 2013-09-20 2014-09-18 前立腺癌を治療するための化合物

Country Status (5)

Country Link
US (2) US10882834B2 (enExample)
EP (1) EP3046561B1 (enExample)
JP (1) JP6564380B2 (enExample)
CA (1) CA2924527C (enExample)
WO (1) WO2015042297A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
JP6000438B2 (ja) * 2012-03-20 2016-09-28 フイルメニツヒ ソシエテ アノニムFirmenich Sa 活性な香料分子の制御放出のための化合物
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP6786520B2 (ja) * 2015-04-21 2020-11-18 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体分解剤(sard)リガンド及びその使用方法
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20170138536A (ko) 2015-04-21 2017-12-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017165822A1 (en) * 2016-03-24 2017-09-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗rsv活性之吡唑并嘧啶
AU2019216260B2 (en) 2018-01-31 2023-03-02 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
CA3095277A1 (en) 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against rsv
WO2020051344A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186205A (en) 1979-01-08 1980-01-29 Smithkline Corporation 2,3-Di(4-substituted phenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
ATE167473T1 (de) 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
NZ512772A (en) 1999-01-08 2003-11-28 Neurogen Corp 1-Phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines useful as dopamine receptor ligands
US6284761B1 (en) 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
JP4409680B2 (ja) 1999-10-18 2010-02-03 株式会社ヤクルト本社 三環性縮合イミダゾール誘導体
JP2001261657A (ja) * 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド (e)−n−ヒドロキシ−3−(3−スルファモイル−フェニル)アクリルアミド化合物及びその治療用途
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
US6680342B2 (en) * 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20060128783A1 (en) 2002-08-09 2006-06-15 Dinsmore Christopher J Tyrosine kinase inhibitors
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
CA2515780C (en) 2003-02-20 2012-12-11 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
JP2009521451A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用な置換アニリン誘導体
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
AU2007290359B2 (en) 2006-09-01 2012-09-20 Vertex Pharmaceuticals Incorporated 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
WO2008060998A1 (en) 2006-11-10 2008-05-22 Wyeth Indole sulfonamides as sfrp-1 modulators
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5587793B2 (ja) 2008-01-23 2014-09-10 エプコス アクチエンゲゼルシャフト 圧電多層構成要素
US9173871B2 (en) * 2008-01-28 2015-11-03 New York University Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
EP2477625A4 (en) 2009-09-14 2012-10-24 Phusis Therapeutics Inc PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
CN102573472A (zh) 2009-10-23 2012-07-11 健康研究公司 治疗雄激素受体阳性癌症的方法
KR20140000695A (ko) 2010-10-14 2014-01-03 미쓰비시 타나베 파마 코퍼레이션 아미드 유도체 및 그 용도
WO2013055793A1 (en) * 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer

Similar Documents

Publication Publication Date Title
JP2016540742A5 (enExample)
JP2019524883A5 (enExample)
JP2014193925A5 (enExample)
JP2015508103A5 (enExample)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
JP2016515561A5 (enExample)
JP2017518959A5 (enExample)
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
JP2016503799A5 (enExample)
JP2016518437A5 (enExample)
AR108203A1 (es) Compuestos, composiciones y métodos para modular cftr (regulador de la conductancia transmembrana de la fibrosis quística)
JP2012529535A5 (enExample)
JP2015024998A5 (enExample)
JP2015509535A5 (enExample)
JP2011037841A5 (enExample)
JP2011524422A5 (enExample)
JP2015522650A5 (enExample)
JP2019500387A5 (enExample)
JP2019510794A5 (enExample)
JP2016531126A5 (enExample)
JP2016531871A5 (enExample)
JP2018135343A5 (enExample)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
RU2018113718A (ru) Новые соединения
JP2014532716A5 (enExample)